-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NasdaqUSDISIN IE00B56GVS15-
ALKERMES PLCBörse Börse MünchenEURSymbol 8AK
-
ALKERMES PLCBörse Quotrix System der Börse DüsseldorfEURSymbol 8AK
-
ALKERMES PLCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol 8AK
-
ALKERMES PLCBörse Börse FrankfurtEURSymbol 8AK
-
ALKERMES PLCBörse Börse DüsseldorfEURSymbol 8AK
-
ALKERMES PLCBörse Börse StuttgartEURSymbol 8AK
-
AlkermesBörse NasdaqISIN IE00B56GVS15 WKN: A1JKVHUSDSymbol ALKS
-
ISIN IE00B56GVS15 WKN: A1JKVHUSDSymbol ALKS
-
ISIN IE00B56GVS15
WKN A1JKVH
Symbol ALKS
Währung
USD
Börse
Nasdaq Zeitzone: America/New_York
Firmenname
Alkermes plc
Marktkapitalisierung
3.786.109.184 (+- 10%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
3.404.218.368 oder 4.168.000.000
Mitarbeiter
2.258 (+- 1%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
2.235 oder 2.280 Mitarbeiter
EBITDA 3.806.000
PEGRatio -1057.29
Buchwert 6.815
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 21,6 EUR +0,93%
Portrait der Alkermes Aktie
Das Unternehmen Alkermes plc aus Irland beschäftigt 2.258 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie tätig.
Das Unternehmen Alkermes plc ist nur in 8 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter iShares Healthcare Innovation UCITS ETF gewichtet Alkermes mit 0,94% im ETF.
Entdecke die 6 ETFs in denen Alkermes plc am höchsten gewichtet ist Insgesamt in 8 ETFs enthalten
Dir gefallen die Informationen zu Alkermes?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Alkermes?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Alkermes?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Alkermes?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
28 News & Informationen zur Alkermes Aktie
5 Best Mid-Cap Stocks For 2021
Alkermes plc (NASDAQ: ALKS) is a biopharmaceutical company with a focus on psychiatric and neurological disorders including schizophrenia as well as alcohol and opioid dependence.
Why Is Alkermes (ALKS) Up 19.4% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au…
Stocks That Hit 52-Week Highs On Monday
Before 10 a.m. ET on Monday, 119 companies hit new 52-week highs.
Noteables: The largest company by market cap to set a new 52-week high was …
Alkermes Plc (ALKS) SVP, CFO Iain Michael Brown Sold $1.2 million of Shares
GuruFocus Article or News written by insider and the topic is about:
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 77 companies hit new 52-week highs.
Areas of Significance: Pfizer (NYSE:PFE) was the largest firm on a market …
2 High-Growth Healthcare Stocks to Buy Right Now By StockNews
2 High-Growth Healthcare Stocks to Buy Right Now
Stocks That Hit 52-Week Highs On Friday
During Friday's morning session, 137 companies made new 52-week highs.
Areas of Significance: Johnson & Johnson (NYSE:JNJ) was the …
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au…
Global Depression Treatment Market (2020 to 2026) – Featuring Allergen, Bausch Health Companies and Lief Therapeutics Among Others
/PRNewswire/ — The
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 167 companies set new 52-week highs.
Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by …
Alkermes plc (ALKS) Q2 2021 Earnings Call Transcript
ALKS earnings call for the period ending June 30, 2021.
Alkermes Q2 2021 Earnings Preview (NASDAQ:ALKS)
Alkermes (NASDAQ:ALKS) is scheduled to announce Q2 earnings results on Wednesday, July 28th, before market open.The consensus EPS Estimate is $0.12 (+100.0% Y/Y) and the consensus…
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was s…
Alkermes Announces Recipients Of 2021 Alkermes Inspiration Grants® Program
DUBLIN, July 23, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced the 2021 recipients of grants from the company's signature Alkermes
Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program
/PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced the 2021 recipients of grants from the company's signature Alkermes Inspiration Grants® program….
Hedge Funds Are Betting On Gibraltar Industries Inc (ROCK)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022
The company operates in three major business segments, Pharmaceuticals, Vaccines and Consumer Healthcare.
Hedge Funds Are Buying Verint Systems Inc. (VRNT)
Is Verint Systems Inc. (NASDAQ:VRNT) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question…
4 Healthcare Stocks to Buy for Growth and Value By StockNews
4 Healthcare Stocks to Buy for Growth and Value
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ju…
Is Liberty Latin America Ltd. (LILAK) A Good Stock To Buy?
In this article we will analyze whether Liberty Latin America Ltd. (NASDAQ:LILAK) is a good investment right now by following the lead of some of the…
Is Alkermes Plc (ALKS) A Good Stock To Buy?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their…
Sarepta, Vertex, Neurocrine: There’s Deep Value In These Beaten Down Healthcare Stocks
Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and stock price returns. Specifically, the theme filters for healthcare companies that have grown revenue by at least 50% over the last three years…
GlaxoSmithKline Taps Goldman and Citi for Consumer Spinoff
(Bloomberg) — GlaxoSmithKline Plc has hired two banks to help advise on plans to list its consumer unit next year and defend against a potential activist campaign from Elliott Investment Management, according to people familiar with the matter.
The U.K.
4 Hot Stocks to Add to Your Growth Portfolio
With interest rates remaining at near-zero levels, supportive government policies have been driving the growth prospects of several companies. As such…
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 12) …
BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021?
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, partly due to Covid-19 related disruptions of the health care industry…